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Abstract
In order to evaluate the critical components
of the process necessary to preserve clinical
plasma samples collected at research sites for
proteomic analysis, various collection and pre-
servation protocols with controlled experi-
mentation were evaluated. The presence of a
protease inhibitor cocktail (PIC) included in the
blood draw tube would stabilize the plasma
proteins was hypothesized. To test this hypoth-
esis, four plasma samples from each of 14 vol-
unteers were collected. Samples were treated
following a standard protocol that included PIC
or were subjected to various processing treat-
ments that included time, temperature, different
anticoagulants, and the absence of PIC. Large
format two dimensional-polyacrylamide gel
electrophoresis (2D-PAGE) proteomic analysis
and enzyme immunoassay (EIA) were used to
detect differences between the treatment groups.
A novel 2D-PAGE quality scoring method was
developed to determine global differences in the
treatment groups, wherein a rating scale ques-
tionnaire was used to quantify the quality of
each 2D-PAGE gel. The data generated from
EIAs, classical 2D-PAGE image analysis and 2D-
PAGE quality scoring, each generated similar
results. Inclusion of protease inhibitor cocktail
in the sample tubes, provided stable and reliable
human plasma samples that yielded repro-
ducible results by proteomic analysis. When PIC
was included, samples retained stability under
less stringent processing, such that refrigeration
for several hours before processing or one
freeze–thaw cycle had little detrimental effect.
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Introduction
Proteomic analysis is now being used exten-
sively for the study of disease through the use
of clinical samples such as tumor cell extracts,
tissue samples, or body fluids (1). Many of
these studies involve the search for biomark-
ers in which certain proteins change in expres-
sion with either a large increase or decrease as
a result of disease (1–4). Two-dimensional
gel electrophoresis (2-DE) remains the most
widely used proteomic technique owing to the
fact that it is currently the method that can
separate and measure hundreds of proteins
from a single biological sample simultane-
ously (5,6). Analysis by 2D-PAGE has been
used for proteomic studies of breast cancer
(7–9), prostate cancer (10,11), hepatocellular
carcinoma (12,13), renal cell carcinoma (14),
rheumatoid arthritis (15,16), and hepatitis B
infection (17). Many of these biomarker stud-
ies utilized human blood serum or plasma
samples. The plasma proteome is now being
widely studied and will be a rich source of
proteins for proteomic analysis for years to
come (18). 
The task of collecting large numbers of clini-
cal plasma samples that best represent, and
most accurately reflect, the plasma composition
in vivo is of great importance. Given the large
number of clinical trial sites around the world,
it is important to standardize a procedure that
will yield reliable samples for proteomic analy-
sis. Clinical samples can be collected and pro-
cessed in any number of ways, but can also be
“mishandled.” Plasma is often collected in a
vacuum drawn blood tube that contains anti-
coagulants and a gel-separating barrier (e.g.
VACUTAINER PPT™, Becton Dickinson,
Franklin Lakes, NJ). There is a great possibility
of lab-to-lab variations in sample handling and
processing and it would be easy to identify, for
instance, biomarkers of proteolysis rather than
markers of a particular disease. The stability of
some analytes, viral load, and a few proteins
from collected plasma samples have been stud-
ied (19–22), but to our knowledge the condition
or stability of the whole plasma proteome from
clinical samples has not been methodically
examined. To minimize the possibility of gen-
erating “artifact” biomarkers, we have devel-
oped a very precise protocol for the collection
of plasma samples from clinical trials. This
protocol includes the addition of a protease
inhibitor cocktail (PIC) directly to plasma col-
lection tubes prior to phlebotomy. Marshall et
al. have recently shown that phenylmethyl-
sulfonyl fluoride (PMSF) and ethylenediamine-
tetraacetic acid (EDTA) effects the stability of
serum samples as judged by matrix assisited
laser desorption/ionization mass spectrometry
(MALDI-MS) (23) while Olivieri et al. have pre-
viously demonstrated protease inhibitors in red
blood cell membrane lysates can have large
effect on 2D-PAGE analysis (24). Here we pre-
sent our findings of controlled treatments of
plasma measured by proteomic analysis.
While it is logical that both a rigorous col-
lection protocol and inclusion of PIC were nec-
essary to obtain high quality plasma samples
for proteomics analysis, neither had been thor-
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We demonstrated that samples without PIC, from
either heparin or ethylenediaminetetraacetic acid
(EDTA) plasma tubes, gave results that varied
significantly from the control samples. Also, even
with PIC present in blood tubes, we found it was
important to quickly decant the separated plasma
from the cellular components found in the blood
tubes following centrifugation, as prolonged
exposure again yielded different results from the
standard procedure.
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oughly evaluated for their ability to preserve
proteins. We therefore designed a series of
handling treatments, with conditions one
might encounter in a clinical setting, to exam-
ine their effects on protein stability and to
detect differences from our standard protocol
(Fig. 1). We wanted to verify that our method
generated stable and high quality plasma sam-
ples. The variables studied centered around
the time and temperature of sample process-
ing, the types of tubes used for sample collec-
tion, and the presence or absence of PIC.
Proteomics is generally considered to be a
global analysis of all proteins in a sample. In
this study, we wanted to achieve the widest
view of the plasma proteins to determine if
differences were present as a result of alter-
ations in the standard protocol. We chose to
use 2D-PAGE on the plasma samples in this
study. In order to limit the variables to mainly
the collection and storage differences, plasma
samples were run with a minimum of sample
preparation. Therefore, samples were not
depleted of high abundance proteins (i.e.,
albumin and immunoglobulin) (25–27) , pre-
fractionated, or run with narrow pI IPG strips
(28–30). The goal was to run more that 50
samples by duplicate 2D-PAGE, measure a
maximum number of spots for each gel and
compare the control group to each of the other
groups treated by the various collection and
processing parameters. For this reason we
chose silver staining of the gels rather than
fluorescent staining, as the latter produced
fewer overall spots, thus fewer data points to
evaluate. Subsequently, the gels were analyzed
using classical image analysis (31,32) , as well
as a novel approach which we term Statistical
2D-PAGE Quality Scoring (SQS). The SQS
method was a semi-quantitative means of
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Fig. 1. Plasma samples collected and treated for study. A total of 56 samples were collected, 4 from each
volunteer, and samples were treated by 8 different handling variations as described (A–H). All the samples
collected were analyzed by EIA and 2D-PAGE (except as noted in results).
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objectively differentiating between good and
bad quality gels. Different aspects and regions
of the gels were scored. Finally, immunoassays
for single proteins, were used as a verification




Four blood samples were drawn into tubes
from 14 healthy volunteers for this study
yielding a total of 56 separate blood samples
for proteomic analysis (Fig. 1). One sample of
blood from each patient was collected in a
tube that was pre-loaded with PIC and han-
dled in accordance with our standard collec-
tion and processing protocol (control group
A). For the control samples, plasma was col-
lected in 8.0 mL lithium heparin plasma sepa-
rating tubes (PST Vacutainer 367965, Becton
Dickinson, Franklin Lakes, NJ) preloaded with
300 µL of PIC (stock: 2.2 mL of water added
to P-2714: Sigma, St. Louis, MO). Each control
tube therefore contained lithium heparin,
EDTA, AEBSF, bestatin, E-64, leupeptin, and
aprotinin. Following blood collection into a
tube the following processing steps were con-
ducted: (1) centrifuge at 2500g for 15 min at 4°C
within 15 min of the draw, (2) aliquot the
plasma layer within 30 min of centrifugation in
1.0 mL volumes, (3) freeze the aliquots imme-
diately using a dry ice/alcohol bath, and (4)
place frozen aliquots in –70°C freezer for stor-
age. The goal was to have each plasma sample
reach solid state within 1 h of venipuncture. 
The remaining three blood samples from
each volunteer were drawn and each sub-
jected to alternate handling and storage treat-
ments that would reasonably be encountered
at research sites participating in clinical trials.
Each of the groups was a variation of the con-
trol protocol and were labeled groups B
through H (six samples per group). For treat-
ment groups A through F, PIC preloaded
VACUTAINERS™ were used, as described in
the previous section. In treatment group B, the
blood was drawn and allowed to remain at
4°C for 5 h prior to the initiation of centrifu-
gation. The remaining steps were performed
as described for the control. Treatment group
C varied from the control only by changing
the freezing temperature to –20°C. In treat-
ment group D, the plasma was decanted after
centrifugation, refrigerated as a bulk aliquot at
4°C for 48 h before the generation of 1.0 mL
aliquots subsequent freezing at –70°C. Treat-
ment group E was processed by storing the
centrifuged VACUTAINER™ at 4°C for 48 h
before aliquotting into 1.0 mL volumes and
freezing. Treatment group F was the result of
snap freezing the decanted bulk plasma fol-
lowing centrifugation, thawing after 48 h,
aliquotting into 1.0 mL volumes, and re-freez-
ing at –70°C. Treatment group G was collected
into two EDTA tubes (VACUTAINER™, no.
362788, 5.0 mL, Becton Dickinson) without
addition of PIC. Treatment group H excluded
the PIC from the lithium heparin VACUTAIN-
ERS™ used in treatment group A, but other-
wise remained unchanged.
Randomization
Samples were randomized prior to the 2D-
PAGE preparation step, the IEF procedure,
and the second dimension run to allow for
more robust statistical analysis. Multiple oper-
ators were used for all steps of 2D-PAGE
including staining and they were blinded to
sample identification. Images for the SQS
assessment were also randomized separately




Sample preparation for 2D-PAGE was con-
ducted according to a protocol described by
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the Two-Dimensional Gel Electrophoresis
Laboratory of Geneva, Switzerland (http://us.
expasy.org/ch2d/service/) (33–35) with some
modification as detailed below. Each sample
was aliquotted in duplicate for two 2D-PAGE
gels. Briefly, a 12.5 µL aliquot of plasma was
mixed with 10 µL of a solution containing 10%
SDS (Fisher Scientific, Fair Lawn, NJ) and
2.3% dithioerythritol (DTE) (Sigma, St. Louis,
MO). The samples were heated to 95°C for
5 min, and subsequently diluted to 500 µL
with solubilization buffer containing 8M urea
(J.T. Baker, Phillipsburg, NJ), 4% Chaps (Cal-
biochem, La Jolla, CA), 40 mM Tris (ICN
Biomedicals, Aurora, OH), 65 mM DTE and
trace Bromphenol blue (Sigma). Protein loads
were based on the average plasma protein
concentration of 80.0 ± 5.5 mg/mL from group
A samples as measured by bicinchoninic acid
(BCA) protein assay (cat. no. 23227; Pierce,
Rockford, IL) (data not shown).
Isoelectric focusing was performed on 18 cm
pH 3.0–10.0 NL IPG strips (Amersham, Piscat-
away, NJ), which were rehydrated overnight
in buffer consisting of 8M urea, 2% Chaps 18
mM DTE, 2% carrier ampholytes (Amersham)
and bromphenol blue at room temperature.
Sixty microliters of the prepared sample was
placed into a cup loader at the anodic end of
the IPG strip while at both electrodes, a paper
wick immersed in a solution of 3.5% DTE was
placed (26) . Each gel consisted of 120 µg ± 7%
of plasma protein. Focusing was performed,
12 strips at a time, on a Protean IEF Cell (Bio-
Rad, Hercules, CA) for a total of 75kVh.
The second dimension sodium dodecyl sul-
fate-polyacrylamide gel electrophoresis (SDS-
PAGE) was performed on 20 × 25 cm 9–16%
gradient Tris gels (Omnimatrix, Yardley, PA).
The gels were run 12 at a time (Dodeca, Bio-
Rad) at 100 V for 16.5 hr, followed by fixation
in 40% methanol, 10% acetic acid for 1 h at
25°C. The gels were silver stained by Silver
Express staining kit (cat. no. LC6100, Invitro-
gen, Carlsbad, CA) as described by the manu-
facturer.
A cooled charge coupled device (CCD)
camera (Fluor-S, cat. no. 1707704; Bio-Rad)
was used to digitize the gel images, using the
same settings for all gels: f-stop = 5.6, expo-
sure = 1.0 s, high resolution setting. Images
were cropped to 757 by 978 pixels for unifor-
mity and then were converted to TIFF files.
These images were analyzed by Progenesis
Discovery software (Version 2003.02; Nonlin-
ear Dynamics, Durham, NC). The analysis
experiment was set up for automated spot
detection and matching, such that the gels
from each treatment set were grouped
together and an average gel image file created.
The average gel from control group A was
selected as the reference gel for the overall
experiment with all 108 gel images. Spots
were detected using the Progenesis algorithm
and “Progenesis background” subtraction
modes. The combined warping and matching
setting was used for gel matching, as was the
“cross-gel detection” which “uses matching
information to make splitting more consistent
within averaged gels.” Unmatched spots were
added to the reference gel and spot numbers
synchronized. The maximum “absence of
spots” allowed per treatment group was set
to three. Normalized spot volumes were
obtained by normalizing to the total spot
volume (total density of image) after using the
Intelligent Noise Correction Algorithm (INCA)
for analysis. No attempt was made to manu-
ally correct mismatched spots so as to keep
the objectivity of automated analysis.
Statistical 2D-PAGE Quality Scoring Analysis 
The 108 randomized 2D-PAGE gel images
were evaluated by five scoring analysts utiliz-
ing a questionnaire with an equal-distance
scoring scale (37) from poor (1) to fair (3) to
excellent (5). Scoring of gel images was done
at random with blinded scorers (2D-PAGE
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operators) to limit the subjectivity (bias). The
scoring scale was used to judge nine criteria:
(1) overall gel image, (2) overall focusing, (3)
overall second dimension quality, (4) overall
streakiness, (5) general image contrast, (6)
albumin/IgG resolution, (7) cluster chain res-
olution, (8) low MW protein resolution, and
(9) basic region resolution. The images were
each scored against two reference gels,
deemed to be of poor or excellent “quality.”
Five scorers were asked to evaluate the
random-ordered gel images in sets of 20–22
per scoring session. The scorers were blinded
to operator and treatment information associ-
ated with the images.
Protein Immunoassays
Enzyme immunoassay (EIA) kits were
chosen based on commercial availability and
applicability to plasma samples. Immunoassay
kits for P-Cadherin (PCAD, cat. no. DPCD0),
and human soluble Vascular Cell Adhesion
Molecule-1 (sVCAM-1, cat. no. BBE3), were
purchased from R & D Systems (Minneapolis,
MN) and used according to the manufacturers
instructions. EIAs were performed in 96-well
plates for all 56 plasma samples in duplicate.
Optical densities were determined by a plate
reader (cat. no. 550, Bio-Rad). Concentrations
of the proteins were calculated by executing a
macro (XLFit, Excel, Microsoft, Redmond,




The spot volume data from matched aver-
age gels were exported from Progenesis to
Excel and scatter-plots were created using
only spots matched by automated matching.
The data was plotted on a log–log scale and
linear regression analysis was done to produce
a linear equation as well as the correlation
coefficient (r2).
Statistical 2D-PAGE Quality Scoring Analysis 
The scores from statistical 2D-PAGE quality
scoring analysis (SQS) of gel images were
compiled and analyzed by the cumula-
tive logistic regression analysis (38) to obtain
the odds ratios for image differences by treat-
ment effect. This gives a prediction of the
probability of one treatment group scoring
higher than another. All the odds ratios were
compared to treatment group A. The operator
and scorer effect were taken into consideration
and were adjusted in the analysis.
Protein Immunoassay Analysis
The analysis of variance (ANOVA) was
applied to test for differences among the treat-
ment groups for each of the proteins measured
by immunoassay. Since four blood tubes were
drawn from each individual, the baseline level
for proteins may be different between individ-
uals. The baseline biological variation was
adjusted for evaluating the treatment effect in
the analysis to prevent confounding (39). 
Results
The plasma samples for this study were col-
lected and processed according to the collec-
tion protocol shown in Fig. 1. Each sample
drawn yielded at least one 1.0 mL aliquot of
plasma, with most yielding three aliquots.
Immunoassays were performed on all 56 sam-
ples and duplicate 2D-PAGE analysis was
done on 54 samples for which there were ade-
quate samples.
Following sample accrual and 2D-PAGE
analysis, all the gel images were processed in
a single analysis set by the Progenesis soft-
ware. An “average gel” was created from each
treatment group, which calculated average
spot volumes for matched protein spots. A
summary of the 2D-PAGE image spot match-
ing analysis where spots from control group A
were matched to each of the other treatment
groups is shown in Table 1. For all 108 gels,
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between 318 and 835 spots were found for
each image. From the automated warping and
matching analysis, 174 to 200 spots from the
control group average gel were matched to
each of the other treatment group’s average
gel data. Figure 2 shows the scatter-plots for
each of the comparisons (control group A vs
groups B through H) using only the matched
spot average volumes. Variation between
groups was determined by linear regression
analysis and was used as a measure of sample
stability. The coefficient of determination (r2
value) from scatter-plots of raw spot volumes
and INCA normalized volumes are also plot-
ted in Fig. 2. The results suggest that treat-
ment groups G and H, which were collected
without PIC, are most different from the con-
trol group. Groups E and F also show more
scatter than the other groups when correlated
to the control group. As we expected, the
more harshly the samples are treated, or in the
absence of PIC, the more scatter is seen in the
spot volume comparisons.
We followed up the previous analysis with
a second analysis of the gel images in order to
get another perspective on the global differ-
ences between treatment groups. A novel
method was used to objectively score the qual-
ity of each gel image. Five analysts scored
nine separate criteria, starting with overall gel
image impression and working towards select
portions of the gel (Fig. 3). The scores from the
SQS process were compiled by treatment
group. Each treatment group was compared to
control group A. Significant odds ratios were
detected from the cumulative logistic regres-
sion. Odds ratios and their 95% confidence
intervals for the “Overall Gel Image” are plot-
ted in Fig. 4. For each scoring criteria, odds
ratios were compiled and those with signifi-
cant differences were ranked in order (Table
2). The results indicated that treatments E, G,
and H repeatedly showed significant differ-
ences from treatment A (Table 2). Even though
group E samples contained PIC, the gel
images from these samples ranked similarly to
treatment group H samples that lacked PIC,
thus leading us to conclude that it is very
important to decant the plasma quickly after
centrifugation. Four of the treatment groups
studied (B–D, and F) showed little difference
from the control group (A). These groups all
contained PIC and were processed either
within 6 h of the blood draw (treatments B
and C) or the bulk plasma was removed from
the collection tube (treatments D and F). In the
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Table 1
2D-PAGE Image Analysis (Detection and Matching) for 108 Gels
Analyzed by Progenesis Discovery Software
Treatment Groups
A B C D E F G H
No. gels per group 126 112 112 110 112 112 112 112
No. spots per
gel (range) 318–779 450–810 428–728 584–692 474–774 449–711 552–835 566–738
No. of spots
matched per set 238 468 396 521 496 425 513 460
(Average gels)
No. spots matched 186 172 200 191 180 178 174














































































































































































































































Fig. 3. 2-D Gel Quality Scoresheet used for Statistical Quality Scoring (SQS). Each of 108 gels were randomly
scored by five scorers using the instructions and scoresheet shown here. Two reference gel images, one of
poor and one of excellent quality, were chosen for the ends of the scoring scale by an experienced operator
who did not take part in the scoring.
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latter two conditions the bulk plasma, now
containing PIC, appeared to show no differ-
ences even though samples sat at 4°C for 48 h
(treatment D) or were exposed to a
freeze–thaw cycle (treatment F). These data
suggest that plasma collected with PIC can
withstand temporary storage at 4°C, tempo-
rary storage of plasma at –20°C, or at least a
single freeze–thaw cycle.
A series of immunoassays were performed
on all 56 plasma samples to provide additional
data to either support or refute our hypothe-
sis. The assays were chosen because kits were
commercially available and were applicable to
plasma samples. Assays for Placental Cad-
herin (PCAD) and soluble Vascular Adhesion
Molecule-1 (sVCAM-1) detected differences
between treatment groups when all samples
were tested. The CVs for test plasma samples
collected using our standard protocol yielded
CVs for intra-assay and inter-assay precision
that were equivalent to those described by the
manufacturer (1.4–1.9% and 4.9–5.9% respec-
tively for PCAD and 4.3–5.9% and 8.5–10.2%
respectively for sVCAM-1 [data not shown]).
To limit variability, samples were thawed
once, randomized and assayed in duplicate.
The PCAD and sVCAM-1 immunoassay
results with descriptive statistics (mean and
standard error) for each treatment group are
shown in Table 3. An analysis of variance
(ANOVA) between control group A and each
of the seven other treatment groups (B–H)
were applied to the immunoassay results
(Table 4). After adjusting for baseline varia-
tion, significant differences among treatments
were observed. As a result, both PCAD and
sVCAM-1 were shown to be present at signif-
icantly higher levels in the plasma in treat-
ment groups G and H (no PIC) as compared
with groups that were drawn with PIC pre-
sent. These two proteins have been reported
as potential biomarkers; PCAD has been
implicated in invasive glandular lesions of the
cervix and colon (40,41), whereas sVCAM-1
has been linked to the development of coro-
nary artery disease and atherosclerosis (42,43).
Discussion
The overall goal of this work was to estab-
lish that our existing sample handling proto-
col, including the protease inhibitor cocktail,
stabilized the proteins in plasma samples col-
lected for proteomic analysis. To test this
hypothesis, three different experimental anal-
yses were used on a total of 56 human plasma
samples collected from 14 separate donors.
The samples were treated according to condi-
tions specified in Fig. 1 in order to mimic con-
ditions anticipated at clinical research sites.
The analyses consisted of a classical spot anal-
ysis of large format 2D gels, a novel scoring
paradigm (SQS) for the same 2D gels, and
immunoassays for individual proteins.
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Fig. 4. The SQS scores for “Overall Gel Image” were
compiled, analyzed by cumulative logistic regression and
the odds ratios for each treatment group compared to
control group A are plotted with a 95% confidence
interval (CI).Treatment groups E, G, and H were found
to be significantly different from the control group A
and are ranked according to odds ratio in Table 2.
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The challenges of 2D-PAGE and image anal-
ysis for clinical samples are many. 2D-PAGE is
not a high-throughput method, and image
analysis—spot detection and matching—
remains less than perfect. Also, because of the
wide dynamic range and presence of highly
abundant proteins, plasma proteomics is a
more difficult task than 2D-PAGE of bacterial
extracts or even human cell extracts (18,28). The
classical scatter-plot analyses, that were used to
compare each treatment group to the control
group (Fig. 2), represent a fairly crude analysis
technique. The statistical certainty was less than
ideal, though there was a definite trend for
samples without PIC (G and H) to be different
from the control. Treatments E and F, where the
samples were treated more harshly, and possi-
bly even B showed slightly more difference
than the groups C and D. While this result with
image analysis supported our hypothesis, rely-
ing on the fit of a straight line to the matched
spots seemed to be an inaccurate means of
assessment. It was reassuring that groups G
(EDTA only), and H (heparin only) showed the
most differences from the control group, but it
was still less than statistically rigorous.
Therefore, an alternative method for statis-
tically assessing gel separation quality was
developed, so as to find meaningful differ-
ences among treatment sets. The idea was to
use the expertise of experienced 2D-PAGE
operators to grade the quality of the 2D-PAGE
separations, and therefore of the plasma sam-
ples themselves. The result, that of the score-
sheet and randomization process described
earlier (Fig. 3), were both surprisingly straight-
forward and reassuringly simple. Unlike the
results from automated spot matching and
scatter-plot analysis, the differences scored
between the control group (A) and treatment
groups G and H were statistically significant
(Table 2). The significant difference between
treatment A and E (48 h refrigeration in col-
lection tube after centrifugation), indicates that
the plasma proteome was affected through
prolonged contact with the cellular material.
One theory is that proteolytic enzymes
excreted from leukocytes diffused through the
gel plug within the blood collection tube and
overwhelmed the PIC, causing proteolysis of
the plasma proteins. Therefore, our collection
and processing protocols now ensure that the
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Table 2
Ranking of Significant Differences for Each of the Nine SQS Criteriaa
Criteria B vs A C vs A D vs A E vs A F vs A G vs A H vs A
Overall Gel Image 2 1 3
Overall focusing 3 1 2
Overall Second Dimension 1
Overall Streakiness 3 1 2
General Contrast 2 1 3
Albumin/IgG Resolution 2 1
Cluster Chain Resolution 3 2 1
Low MW Protein Resolution 1 2 3
Basic Region resolution 2 1
aOdds ratios with 95% confidence interval, like that plotted in Fig. 4, yielded significant differences which are
ranked for each scoring criteria. Rank is solely based on the odds ratio estimate, not statistically tested.
Note: Groups E, G, and H consistently scored significantly different than A in most of the nine quality crite-
ria. There were no significant differences between groups B, C, or D compared to control group A.
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sample tubes are centrifuged and decanted
within 1 h of blood draw, and that this length of
time must be closely monitored and recorded.
This data implicates that biomarker “artifacts”
may result from extended incubation of blood
components without separation. The results of
treatment groups G and H showed a benefit
from the inclusion of the protease inhibitors
other than just EDTA. A possible future experi-
ment would be to test blood samples for pro-
tease activity directly (for example, using
Zymogram gels). Finally, the nonsignificance
among groups A–D and possibly F, indicates
that the presence of PIC allowed for less expe-
ditious processing and/or less rigorous storage
conditions.
Results from gels from samples without PIC
(G and H), and the samples left in a VACU-
TAINER™ for 48 h at 4°C (E), were clearly rec-
ognized by the SQS analysis as being distinct
from the other 2D-PAGE separations. To this
end, the SQS process demonstrated its useful-
ness. This methodology of scoring gel quality
may be used for future clinical studies per-
formed with 2D-PAGE analysis. It may also be
possible to use SQS as a first pass test to deter-
mine if there are statistical differences in two
sets of gels from a proteomic project prior to
the use of computed image analysis. The
results of SQS also proved to be readily man-
ageable by statistical data analysis. A weighted
score for each of the scoring criteria can be
easily implemented to refine the SQS process
to address more interesting questions.
Recognizing that the 2D-PAGE was a global
approach, we searched for individual protein
differences by spot volume analysis that
would match the trends seen in the global
analysis, however there was too much varia-
tion in the data. By using immunoassays we
did find two proteins that changed signifi-
cantly by treatment. These assays proved to be
a high-throughput means of testing all sam-
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Table 3
Results of Immunoassays of Human Soluble Placental cCadherin (PCAD) and Human Soluble Vascular
Adhesion Molecule-1 (sVCAM-1) for 56 Plasma Samples Collected for the Stability Studya
Treatment Groups
Protein Statistics A B C D E F G H
PCAD mean 9.203 9.451 9.022 10.088 9.645 9.030 11.094 11.494
SD 1.691 1.615 1.742 2.217 1.875 1.582 0.908 1.367
sVCAM mean 241.993 235.487 196.315 227.756 273.396 282.871 766.919 396.786
SD 99.457 89.596 92.618 85.906 133.166 89.381 239.811 109.271
aResults for mean concentration (ng/mL) with standard deviations (SD) for each treatment group are shown.
Table 4
ANOVA Analysis (p values) of EIA Concentration
Values From Each Treatment Group
Compared to the Control Group
Contrast PCAD sVCAM-1
B vs A <0.4720 <0.9812
C vs A <0.4623 <0.7504
D vs A <0.2450 <0.8137
E vs A <0.5575 <0.6152
F vs A <0.2770 <0.7109
G vs A <0.0001 <0.0001
H vs A <0.0001 <0.0003
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ples in a much shorter timeframe, and at
significantly lower cost, than the 2D-PAGE
method. The two proteins, PCAD and
sVCAM-1, were known to be found in soluble
and cell-bound forms, and we theorized that
an increase in the soluble form in plasma
would be because of proteolysis or cell lysis
during collection and handling of the blood
samples. The fact that both PCAD and
sVCAM-1 were found at higher levels in treat-
ment groups G and H vs the control group A
indicates that both of these proteins are most
likely cleaved by nonmetalloproteases and
that the presence of the PIC substantially
increases the stability of their membrane-
bound forms. As surrogates for the rest of the
plasma proteome, we infer that other proteins
are certain to be similarly affected by the
absence of protease inhibitors. The immunoas-
say results corroborated the various 2D-PAGE
gel analysis methods, in showing that treat-
ment groups G (EDTA only) and H (no pro-
tease inhibitors), the two groups without PIC,
were again significantly different from the
control group A. The increase in soluble
PCAD or sVCAM-1 in these two groups sug-
gests that they could serve as reporter proteins
for proper collection or stability of plasma
samples. They may be surrogate markers of
plasma sample reliability.
Conclusions
As an overall assessment, each of the tech-
niques and analysis methods showed remark-
ably consistent results, that our standard
collection protocol, including the protease
inhibitor cocktail, provides for the most stable
human plasma samples for proteomic analy-
sis. There were indications that some of the
strict aliquotting and time restraints could
be relaxed, given the presence of the PIC,
although there was clearly a need to separate
the cellular component of blood from the
plasma as soon as possible, via centrifugation
and decanting. Freeze–thaw cycles and tem-
porary refrigeration both seemed to have little
detrimental affect in the presence of PIC.
The goals of the experiments also drove the
creation of the novel statistical scoring method
(SQS). This method could be used in the
future for the development of enhanced 2D-
PAGE methods, both by vendors and end-
users in clinical studies. It provides a robust
means of differentiating subtleties in 2D-PAGE
performance, and can be implemented with-
out the need for extensive computational anal-
ysis hardware or software. We recognize that
there are many new mass spectrometry tech-
nologies being used for proteomics analysis
but 2D-PAGE analysis is still a common
and important tool for plasma and serum pro-
filing. Not surprisingly, immunoassays for
specific proteins are a simple, fast, and inex-
pensive way to validate sample stability or
biomarker assessment, limited only by kit
availability. Finally, if one adheres to our
protocol for clinical plasma collection that
includes protease inhibitors, even with the
wide range of collection variability in research
laboratories, there appears to be little need to
worry about the integrity of the samples.
Acknowledgments
The authors are grateful for the assistance
of Elizabeth B. Hierl, Susan Lubin, and Lisu
Wang, all of BMS-Hamilton, without whom
this project would not have been possible. We
are also indebted to Estelle M. Fach, Leah Ann
Garulacan, Ji Gao, and Qing Xiao of BMS-
Hopewell for their help running and scoring
the 2D-PAGE gels. Thanks also to Thomas
Colarusso and Christina Pavlick, of Nonlinear
and Bio-Rad, respectively, who aided us in the
area of 2D-PAGE image analysis. Dr. Kim E.
Zerba helped us tremendously with the bio-
Plasma Stabilization _________________________________________________________________________ 29
Clinical Proteomics _______________________________________________________________ Volume 1, 2004
statistics. Finally, JDH thanks Patricia E. Hulmes
for her valuable advice on questionnaire
scoring.
References
1. Hanash S. Disease proteomics. Nature 2003;
422:226–232.
2. Hanash SM. Biomedical applications of two-
dimensional electrophoresis using immobilized
pH gradients: current status. Electrophoresis
2000;21:1202–1209.
3. Chambers G, Lawrie L, Cash P, Murray GI.
Proteomics: a new approach to the study of
disease. J Pathol 2000;192:280–288.
4. Seliger B, Kellner R. Design of proteome-
based studies in combination with serology
for the identification of biomarkers and novel
targets. Proteomics 2002;2:1641–1651.
5. Rabilloud T. Two-dimensional gel electro-
phoresis in proteomics: old, old fashioned, but
it still climbs up the mountains. Proteomics
2002;2:3–10.
6. Young DS, Tracy RP. Clinical applications of
two-dimensional electrophoresis. J Chroma-
togr A 1995; 698:163–179.
7. Le Naour F, Misek DE, Krause MC, et al. Pro-
teomics-based identification of RS/DJ-1 as a
novel circulating tumor antigen in breast
cancer. Clin Cancer Res 2001;7:3328–3335.
8. Rui Z, Jian-Guo J, Yuan-Peng T, Hai P, Bing-
Gen R. Use of serological proteomic methods
to find biomarkers associated with breast
cancer. Proteomics 2003;3:433–439.
9. Zuo X, Hembach P, Echan L, Speicher DW.
Enhanced analysis of human breast cancer
proteomes using micro-scale solution isoelec-
trofocusing combined with high resolution
1-D and 2-D gels. J Chromatogr B Analyt
Technol Biomed Life Sci 2002;782:253–265.
10. Charrier JP, Tournel C, Michel S, et al.
Differential diagnosis of prostate cancer
and benign prostate hyperplasia using two-
dimensional electrophoresis. Electrophoresis
2001;22:1861–1866.
11. Charrier JP, Tournel C, Michel S, Dalbon P,
Jolivet M. Two-dimensional electrophoresis of
prostate-specific antigen in sera of men with
prostate cancer or benign prostate hyperpla-
sia. Electrophoresis 1999;20:1075–1081.
12. Poon TC, Johnson PJ. Proteome analysis and
its impact on the discovery of serological
tumor markers. Clin Chim Acta 2001;313:
231–239.
13. Steel LF, Shumpert D, Trotter M, et al. A strat-
egy for the comparative analysis of serum
proteomes for the discovery of biomarkers for
hepatocellular carcinoma. Proteomics 2003;3:
601–609.
14. Kellner R, Lichtenfels R, Atkins D, et al. Tar-
geting of tumor associated antigens in renal
cell carcinoma using proteome-based analysis
and their clinical significance. Proteomics
2002;2:1743–1751.
15. Sinz A, Bantscheff M, Mikkat S, et al. Mass
spectrometric proteome analyses of synovial
fluids and plasmas from patients suffering
from rheumatoid arthritis and comparison to
reactive arthritis or osteoarthritis. Electro-
phoresis 2002;23:3445–3456.
16. Smith MA, Bains SK, Betts JC, Choy EH, Zan-
ders ED. Use of two-dimensional gel elec-
trophoresis to measure changes in synovial
fluid proteins from patients with rheumatoid
arthritis treated with antibody to CD4. Clin
Diagn Lab Immunol 2001;8:105–111.
17. He QY, Lau GK, Zhou Y, et al. Serum bio-
markers of hepatitis B virus infected liver
inflammation: A proteomic study. Proteomics
2003;3:666–674.
18. Anderson NL, Anderson NG. The human
plasma proteome: history, character, and diag-
nostic prospects. Mol Cell Proteomics 2003;
2:50.
19. Boyanton BL, Jr., Blick KE. Stability studies of
twenty-four analytes in human plasma and
serum. Clin Chem 2002;48:2242–2247.
20. Flower L, Ahuja RH, Humphries SE,
Mohamed-Ali V. Effects of sample handling
on the stability of interleukin 6, tumour necro-
sis factor-alpha and leptin. Cytokine 2000;12:
1712–1716.
21. Lewis MR, Callas PW, Jenny NS, Tracy RP.
Longitudinal stability of coagulation, fibrinol-
ysis, and inflammation factors in stored
plasma samples. Thromb Haemost 2001;86:
1495–1500.
22. Holodniy M, Rainen L, Herman S, Yen-
Lieberman B. Stability of plasma human
immunodeficiency virus load in VACUTAINER
PPT plasma preparation tubes during overnight
shipment. J Clin Microbiol 2000;38:323–326.
23. Marshall J, Kupchak P, Zhu W, et al. Process-
ing of Serum Proteins Underlies the Mass
30 _______________________________________________________________________________ Hulmes et al.
Volume 1, 2004 _______________________________________________________________ Clinical Proteomics
Spectral Fingerprinting of Myocardial Infarc-
tion. J Proteome Res. 2003;2:361–372.
24. Olivieri E, Herbert B, Righetti PG. The effect
of protease inhibitors on the two-dimensional
electrophoresis pattern of red blood cell mem-
branes. Electrophoresis 2001;22:560–565.
25. Lollo BA, Harvey S, Liao J, et al. Improved
two-dimensional gel electrophoresis represen-
tation of serum proteins by using ProtoClear.
Electrophoresis 1999;20:854–859.
26. Wang YY, Cheng P, Chan DW. A simple affin-
ity spin tube filter method for removing high-
abundant common proteins or enriching
low-abundant biomarkers for serum pro-
teomic analysis. Proteomics 2003;3:243–248.
27. Rothemund DL, Locke VL, Liew A, Thomas
TM, Wasinger V, Rylatt DB. Depletion of the
highly abundant protein albumin from human
plasma using the Gradiflow. Proteomics 2003;
3:279–287.
28. Corthals GL, Wasinger VC, Hochstrasser DF,
Sanchez JC. The dynamic range of protein
expression: a challenge for proteomic research.
Electrophoresis 2000;21:1104–1115.
29. Herbert B, Righetti PG. A turning point in
proteome analysis: sample prefractionation
via multicompartment electrolyzers with iso-
electric membranes. Electrophoresis 2000;21:
3639–3648.
30. Zuo X, Echan L, Hembach P, et al. Towards
global analysis of mammalian proteomes
using sample prefractionation prior to narrow
pH range two-dimensional gels and using
one-dimensional gels for insoluble and large
proteins. Electrophoresis 2001;22:1603–1615.
31. Collins PJ, Juhl C, Lognonne JL. Image analy-
sis of 2D gels: considerations and insights.
Cell Mol Biol (Noisy-le-grand) 1994;40:77–83.
32. Nishihara JC, Champion KM. Quantitative eval-
uation of proteins in one- and two-dimensional
polyacrylamide gels using a fluorescent stain.
Electrophoresis 2002;23:2203–2215.
33. Hughes GJ, Frutiger S, Paquet N, et al. Plasma
protein map: an update by microsequencing.
Electrophoresis 1992; 13:707–714.
34. Sanchez JC, Appel RD, Golaz O, et al. Inside
SWISS-2DPAGE database. Electrophoresis
1995;16:1131–1151.
35. Hoogland C, Sanchez JC, Walther D, et al.
Two-dimensional electrophoresis resources
available from ExPASy. Electrophoresis 1999;
20:3568–3571.
36. Hoving S, Gerrits B, Voshol H, Muller D,
Roberts RC, van Oostrum J. Preparative two-
dimensional gel electrophoresis at alkaline pH
using narrow range immobilized pH gradi-
ents. Proteomics 2002;2:127–134.
37. Streiner DL. A checklist for evaluating the use-
fulness of rating scales. Can J Psychiatry 1993;
38:140–148.
38. Agresti A. Analysis of Ordinal Categorical
Data. New York: John Wiley & Sons, Inc.,1984.
39. Rhodes AE, Lin E, Streiner DL. Confronting
the confounders: the meaning, detection, and
treatment of confounders in research. Can J
Psychiatry 1999;44:175–179.
40. Han AC, Edelson MI, Peralta Soler A, et al.
Cadherin expression in glandular tumors of
the cervix. Cancer 2000;89:2053–2058.
41. Muller N, Reinacher-Schick A, Baldus S,
et al. Smad4 induces the tumor suppressor
E-cadherin and P-cadherin in colon carcinoma
cells. Oncogene 2002;21:6049–6058.
42. Blankenberg S, Rupprecht HJ, Bickel C, et al.
Circulating cell adhesion molecules and death
in patients with coronary artery disease. Cir-
culation 2001;104:1336–1342.
43. Cybulsky MI, Iiyama K, Li H, et al. A major
role for VCAM-1, but not ICAM-1, in early
atherosclerosis. J Clin Invest 2001;107:1255–1262.
Plasma Stabilization _________________________________________________________________________ 31
